Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1967 |
Name | leiomyosarcoma |
Definition | A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer muscle cancer smooth muscle cancer leiomyosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 positive | PD173074 | leiomyosarcoma | decreased response | detail... |
FGFR1 positive | AZD4547 | leiomyosarcoma | decreased response | detail... |
FGFR1 positive | Infigratinib | leiomyosarcoma | decreased response | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
NCT01446809 | Phase I | Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib | Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01498484 | Phase II | EB-VST cells | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | Completed | USA | 0 |
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
NCT02303262 | Phase II | Gemcitabine + Mocetinostat | A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma | Completed | USA | 0 |
NCT02406781 | Phase II | Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) | Unknown status | FRA | 0 |
NCT02584309 | Phase II | Dexrazoxane Doxorubicin + Olaratumab | Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02601209 | Phase Ib/II | Pazopanib Sapanisertib | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Terminated | USA | 0 |
NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Active, not recruiting | USA | 0 |
NCT02923778 | Phase II | Talimogene laherparepvec | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
NCT02987959 | Phase II | Sapanisertib | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Terminated | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03016819 | Phase III | Anlotinib Dacarbazine | A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS) | Active, not recruiting | USA | ITA | GBR | ESP | 1 |
NCT03074318 | Phase Ib/II | Avelumab + Trabectedin | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT03114527 | Phase II | Everolimus + Ribociclib | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | Active, not recruiting | USA | 0 |
NCT03277924 | Phase Ib/II | Nivolumab + Sunitinib | Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) | Recruiting | ITA | GBR | ESP | 0 |
NCT03282344 | Phase II | Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03437070 | Phase I | Doxorubicin + Olaratumab + Trabectedin | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | Withdrawn | 0 | |
NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Recruiting | GBR | FRA | 0 |
NCT03548428 | Phase II | Atezolizumab | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) | Recruiting | FRA | 0 |
NCT03670069 | Phase I | Itacitinib | Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03718091 | Phase II | Berzosertib | M6620 (VX-970) in Selected Solid Tumors | Completed | USA | 0 |
NCT03719430 | Phase II | APX005M + Doxorubicin + Olaratumab | APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma | Recruiting | USA | 0 |
NCT03761095 | Phase I | Dacarbazine + PTC596 | A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | Active, not recruiting | USA | 0 |
NCT03793361 | Phase II | Regorafenib | Phase II Study of Regorafenib as Maintenance Therapy | Suspended | FRA | 0 |
NCT03851614 | Phase II | Cediranib + Durvalumab Durvalumab + Olaparib | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | Active, not recruiting | CAN | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03899805 | Phase II | Eribulin + Pembrolizumab | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111 | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04076579 | Phase II | Olaparib + Trabectedin | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT04200443 | Phase II | Cabozantinib + Temozolomide | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Recruiting | FRA | 0 |
NCT04242238 | Phase I | Avelumab + Vimseltinib | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Active, not recruiting | USA | 0 |
NCT04383119 | Phase II | Gemcitabine Trabectedin | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (ISG-ARTICLE) | Recruiting | ITA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04535271 | Phase II | Dacarbazine + Gemcitabine + Trabectedin | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma | Recruiting | USA | 0 |
NCT04595994 | Phase I | Selinexor | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma | Active, not recruiting | ESP | 0 |
NCT04624178 | Phase II | Nivolumab + Rucaparib | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | Active, not recruiting | USA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04807816 | Phase II | Berzosertib + Gemcitabine Gemcitabine | Targeting ATR in Soft-tissue Sarcomas (TARSARC) | Recruiting | FRA | 0 |
NCT04811196 | Phase I | Selinexor | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | Recruiting | CAN | 0 |
NCT04874311 | Phase II | Bintrafusp alfa + Doxorubicin Doxorubicin | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) | Recruiting | FRA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04906876 | Phase II | 9-ING-41 + Docetaxel + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT04996004 | Phase Ib/II | Doxorubicin + TTI-621 | A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma | Active, not recruiting | USA | 0 |
NCT05043649 | Phase I | Camsirubicin + Pegfilgrastim | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Recruiting | USA | 0 |
NCT05080790 | Phase II | Aldesleukin + Dinutuximab + Zoledronic acid | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) | Recruiting | DEU | 0 |
NCT05116683 | Phase II | ATX101 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101) | Terminated | USA | 0 |
NCT05116800 | Phase II | 9-ING-41 + Docetaxel + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05174455 | Phase II | Niraparib | Niraparib for the Treatment of Leiomyosarcoma | Withdrawn | 0 | |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05711615 | Phase I | Pegylated liposomal doxorubicin + Peposertib | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Suspended | USA | 0 |
NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Recruiting | ESP | 0 |
NCT05821231 | Phase I | MEDI5752 | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT) | Recruiting | FRA | 0 |
NCT05836571 | Phase II | Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05879185 | Phase II | Izuralimab | A Study of XmAb23104 in People With Sarcoma | Active, not recruiting | USA | 0 |
NCT06114004 | Phase II | Gemcitabine + Selinexor | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) (SeliSarc) | Recruiting | ESP | 0 |